表4_新辅助PD-1阻断联合化疗后同步免疫放疗治疗局部晚期肛管鳞状细胞癌患者：抗肿瘤疗效、安全性和生物标志物分析

数据集获取（Figshare）

• 源站标题：Table_4_Neoadjuvant PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy in Locally Advanced Anal Canal Squamous Cell Carcinoma Patients: Antitumor Efficacy, Safety and Biomarker Analysis.xlsx
• DOI：10.3389/fimmu.2021.798451.s006
• 发布日期：2022-01-14
• 文件数：1 个
• 文件总体积：1.60 MB
• 源站页面：https://frontiersin.figshare.com/articles/dataset/Table_4_Neoadjuvant_PD-1_Blockade_Combined_With_Chemotherapy_Followed_by_Concurrent_Immunoradiotherapy_in_Locally_Advanced_Anal_Canal_Squamous_Cell_Carcinoma_Patients_Antitumor_Efficacy_Safety_and_Biomarker_Analysis_xlsx/18392177

命令行下载

curl -L -o "Table_4_Neoadjuvant PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy in Locally Advanced Anal Canal Squamous Cell Ca.xlsx" "https://ndownloader.figshare.com/files/33155384"

文件清单

• Table_4_Neoadjuvant PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy in Locally Advanced Anal Canal Squamous Cell Ca.xlsx（1.60 MB）

文件总体积 1.60 MB（源站 API 实测）。

数据说明

BackgroundAnal canal squamous cell carcinoma (ACSCC) is an exceedingly rare malignant neoplasm with challenges in sphincter preservation, treatment toxicities and long-term survival. Little is known concerning the activity of PD-1 antibodies in locally advanced ACSCC. This study reports on the efficacy and toxicities of a neoadjuvant PD-1 blockade combined with chemotherapy followed by concurrent immunoradiotherapy in ACSCC patients, and describes biomarkers expression and mutation signatures.
MethodsIn this cohort study, patients were treated as planned, including four cycles of neoadjuvant PD-1 antibody toripalimab combined with docetaxol and cisplatin, followed by radiotherapy and two cycles of concurrent toripalimab. Multiplex immunofluorescence staining (mIHC) with PD-L1, CD8, CD163, Pan-Keratin and DAPI was performed with the pretreatment tumor tissue. Whole exome sequencing was performed for the primary tumor and peripheral blood mononuclear cells. The primary endpoint was the complete clinical response (cCR) rate at 3 months after overall treatment. Acute and late toxicities graded were assessed prospectively.
ResultsFive female patients with a median age of 50 years old (range, 43-65 years old), finished treatment as planned. One patient had grade 3 immune related dermatitis. Two patients had grade 3 myelosuppression during neoadjuvant treatment. No severe radiation-related toxicities were noted. Four patients with PD-L1 expression >1% achieved a cCR after neoadjuvant treatment. and the other patient with negative PD-L1 expression also achieved a cCR at 3 months after radiotherapy. All the patients were alive and free from disease and had a normal quality of life, with 19.6-24 months follow up. Inconsistent expression of PD-L1 and CD163 was detected in 3 and 5 patients, respectively. TTN, POLE, MGAM2 were the top mutation frequencies, and 80 significant driver genes were identified. Pathway analysis showed enrichment of apoptosis, Rap1, Ras, and pathways in cancer signaling pathways. Eight significantly deleted regions were identified.
ConclusionsThis small cohort of locally advanced ACSCC patients had quite satisfactory cCR and sphincter preservation r

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.3389/fimmu.2021.798451.s006（source: https://frontiersin.figshare.com/articles/dataset/Table_4_Neoadjuvant_PD-1_Blockade_Combined_With_Chemotherapy_Followed_by_Concurrent_Immunoradiotherapy_in_Locally_Advanced_Anal_Canal_Squamous_Cell_Carcinoma_Patients_Antitumor_Efficacy_Safety_and_Biomarker_Analysis_xlsx/18392177）。